These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8318411)

  • 1. Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers?
    Dixon AR; Jackson L; Chan SY; Badley RA; Blamey RW
    Br J Cancer; 1993 Jul; 68(1):181-5. PubMed ID: 8318411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Objective measurement of therapeutic response in breast cancer using tumour markers.
    Robertson JF; Pearson D; Price MR; Selby C; Blamey RW; Howell A
    Br J Cancer; 1991 Oct; 64(4):757-63. PubMed ID: 1911226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer.
    Robertson JF; Jaeger W; Syzmendera JJ; Selby C; Coleman R; Howell A; Winstanley J; Jonssen PE; Bombardieri E; Sainsbury JR; Gronberg H; Kumpulainen E; Blamey RW
    Eur J Cancer; 1999 Jan; 35(1):47-53. PubMed ID: 10211087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.
    Yamao T; Kai S; Kazami A; Koizumi K; Handa T; Takemoto N; Maruyama M
    Jpn J Clin Oncol; 1999 Nov; 29(11):550-5. PubMed ID: 10678558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study.
    Martoni A; Zamagni C; Bellanova B; Zanichelli L; Vecchi F; Cacciari N; Strocchi E; Pannuti F
    Eur J Cancer; 1995 Sep; 31A(10):1615-21. PubMed ID: 7488411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological monitoring of advanced breast cancer treated by systemic cytotoxic using a combination of ESR, CEA, and CA 15.3: fact or fiction?
    Dixon AR; Jönrup I; Jackson L; Chan SY; Badley RA; Blamey RW
    Dis Markers; 1991; 9(3-4):167-74. PubMed ID: 1813208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Follow-up of tumor markers in evaluating the effectiveness of chemo- or hormone therapy in metastatic breast cancer].
    Möbus V; Paula J; Beck T; Crombach G; Kreienberg R
    Geburtshilfe Frauenheilkd; 1993 Jan; 53(1):24-9. PubMed ID: 8440454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy.
    Cheung KL; Evans AJ; Robertson JF
    Breast Cancer Res Treat; 2001 Jun; 67(3):273-8. PubMed ID: 11561773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer.
    Loprinzi CL; Tormey DC; Rasmussen P; Falkson G; Davis TE; Falkson HC; Chang AY
    J Clin Oncol; 1986 Jan; 4(1):46-56. PubMed ID: 3510282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
    Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
    J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy.
    Classen S; Kopp R; Possinger K; Weidenhagen R; Eiermann W; Wilmanns W
    Tumour Biol; 2002; 23(2):70-5. PubMed ID: 12065844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up.
    Harbeck N; Untch M; Pache L; Eiermann W
    Br J Cancer; 1994 Mar; 69(3):566-71. PubMed ID: 7510120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
    Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
    J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of five serum marker assays in patients with advanced breast cancer treated with medroxyprogesterone acetate.
    Murray A; Clinton O; Earl H; Price M; Moore A
    Eur J Cancer; 1995 Sep; 31A(10):1605-10. PubMed ID: 7488409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of predictive markers for patients with advanced colorectal cancer.
    Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
    Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF.
    Poikonen P; Saarto T; Lundin J; Joensuu H; Blomqvist C
    Br J Cancer; 1999 Aug; 80(11):1763-6. PubMed ID: 10468293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.
    Rack B; Jückstock J; Trapp E; Weissenbacher T; Alunni-Fabbroni M; Schramm A; Widschwendter P; Lato K; Zwingers T; Lorenz R; Tesch H; Schneeweiss A; Fasching P; Mahner S; Beckmann MW; Lichtenegger W; Janni W;
    Tumour Biol; 2016 Oct; 37(10):13769-13775. PubMed ID: 27481512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
    Mansour EG; Gray R; Shatila AH; Osborne CK; Tormey DC; Gilchrist KW; Cooper MR; Falkson G
    N Engl J Med; 1989 Feb; 320(8):485-90. PubMed ID: 2915651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.